- Home
- ALGS vs LSTA Comparison
ALGS vs LSTA Comparison
Compare ALGS & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALGS | LSTA |
|---|---|---|
| Founded | 2018 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Misc Health and Biotechnology Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.6M | 28.9M |
| IPO Year | 2020 | 2000 |
Fundamental Metrics
Financial Performance| Metric | ALGS | LSTA |
|---|---|---|
| Price | $5.59 | $1.06 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $39.33 | $15.00 |
| AVG Volume (30 Days) | 105.2K | ★ 121.5K |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 88.30 | 20.42 |
| EPS | N/A | ★ N/A |
| Revenue | $2,186,000.00 | ★ $35,283,868.00 |
| Revenue This Year | $32.20 | N/A |
| Revenue Next Year | $4.71 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 56.90 |
| 52 Week Low | $3.98 | $0.99 |
| 52 Week High | $13.69 | $5.07 |
Technical Indicators
Market Signals| Indicator | ALGS | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 56.92 | 19.37 |
| Support Level | $4.80 | N/A |
| Resistance Level | $5.94 | $2.19 |
| Average True Range (ATR) | 0.50 | 0.20 |
| MACD | 0.06 | -0.08 |
| Stochastic Oscillator | 84.07 | 3.23 |
Price Performance
Historical ComparisonAbout ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.